What You Need to Know
• Alibaba and AUS Merchant Services Inc. failed to prevent the sale of dangerous drugs to U.S. customers for eight years.
• The U.S. Department of Justice resolved the case for $600 million in penalties and a non-prosecution agreement.
• Prosecutors believed they had sufficient evidence for felony violations of the Food, Drug and Cosmetic Act.
Chinese online retailer Alibaba Group Holding Limited and its U.S. payment processing subsidiary, AUS Merchant Services Inc., were found to have inadequately prevented the sale of hazardous drugs, chemicals, and pill presses to American consumers over an eight-year period. Despite warnings from employees about compliance issues, the U.S. Department of Justice believed there was enough evidence to pursue felony charges under the Food, Drug and Cosmetic Act. The case, which began during the Trump administration, gained momentum under the Biden administration, leading to a resolution that involved $600 million in penalties and a non-prosecution agreement, where the companies admitted to lesser misdemeanor violations. This outcome has been criticized by some as insufficient given the severity of the alleged conduct.
Why It Matters
This case illustrates ongoing challenges in regulating online marketplaces and ensuring compliance with health and safety laws. The Food, Drug and Cosmetic Act, enacted in 1938, is designed to protect consumers from counterfeit and unsafe products. The resolution of this case reflects broader trends in the Justice Department’s handling of corporate violations, where significant penalties have sometimes been avoided. The decision to settle for lesser charges raises concerns about the effectiveness of legal frameworks in holding corporations accountable for public health risks.
Read the Full Story →
